SynthesisFrontiers in cellular and infection microbiology2023
Synthesis in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Association of Klebsiella pneumoniae sequence type 11 but not other virulence factors with patient mortality: a systematic review and meta-analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Pooled it
- Antibiotic resistance in hospital wastewater in West Africa: a systematic review and meta-analysis.BMC public health · 2025Pooled it
- RecCVirulence · 2026Article
- Molecular characterisation of extended-Spectrum-Beta-lactamase-producingOne health (Amsterdam, Netherlands) · 2026Article
- Phage vB_KpnM_NB cocktail synergizing with amikacin in inhibiting persister cells ofApplied and environmental microbiology · 2026Article
- Ceftazidime-Avibactam Versus Colistin-Based Regimens for Carbapenem-Resistant Enterobacterales Bloodstream Infections: A Six-Year Retrospective Cohort and 30-Day Mortality Analysis.Microorganisms · 2026Article
- Increase in Healthcare-Associated Infections: Is COVID-19 Responsible? A Narrative Review.Microorganisms · 2026Review
- Molecular Characterization and Clinical Outcomes ofChildren (Basel, Switzerland) · 2026Article
- Risk factors for polymicrobial klebsiella pneumoniae bloodstream infection: a retrospective cohort study using the antimicrobial resistance monitoring database.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Carbapenem-ResistantMicroorganisms · 2026Review
- KPC-producing Klebsiella pneumoniae in Switzerland from 2024 to 2025: comparative genomics and cefiderocol resistance mechanisms analyses.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Infectious pathogens associated with stillbirth and under-five mortality by sickle cell disease in Western Kenya: a cross-sectional study.BMC infectious diseases · 2026Article
- Incidence of colonization and infection with carbapenemase-producing Enterobacterales in Toronto and Peel Region, Ontario, 2007-2024.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2026Article
- Multidrug-resistant Klebsiella pneumoniae in oncology intensive care units: selected genetic markers and clinical predictors.Infection · 2026Article
- Characterization of Proline-Rich Antimicrobial Peptides with SbmA Transporter-Dependent and Independent Antimicrobial Activity towardACS infectious diseases · 2026Article
- Prevalence of extended-spectrum β-lactamase and carbapenemase-producing Klebsiella pneumoniae in humans, animals and the environment in Northwest Amhara, Ethiopia.Scientific reports · 2026Article
- Clinically Significant Carbapenemases in Gram-Negative Pathogens: Molecular Diversity and Advances in β-Lactamase Inhibitor Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- Exploratory association between multimodal AI-derived digital biomarkers and in-hospital mortality in adult patients with pneumonia: A proof-of-concept study.PLOS digital health · 2026Article
- Characterization of multidrug-resistant ST978-KL103Microbiology spectrum · 2026Article
- Phenotypic and genomic characterization of tigecycline heteroresistance in carbapenem-resistantMicrobiology spectrum · 2026Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the mortality rate of patients with Methods: EMbase, Web of Science, PubMed, and The Cochrane Library were searched up to September 18 Results: A total of 157 studies (37,915 enrolled patients) were included in the meta-analysis. The pooled death proportions of KPB were 17% (95% CI=0.14-0.20) at 7-day, 24% (95% CI=0.21-0.28) at 14-day, 29% (95% CI=0.26-0.31) at 30-day, 34% (95% CI=0.26-0.42) at 90-day, and 29% (95% CI=0.26-0.33) in hospital, respectively. Heterogeneity was found from the intensive care unit (ICU), hospital-acquired (HA), CRKP, and ESBL-KP in the meta-regression analysis. More than 50% of ICU, HA, CRKP, and ESBL-KP were associated with a significant higher 30-day mortality rates. The pooled mortality odds ratios (ORs) of CRKP Conclusions: This meta-analysis indicated that patients with KPB in ICU, HA-KPB, CRKP, and ESBL-KP bacteremia were associated with a higher mortality rate. The high mortality rate caused by CRKP bacteremia has increased over time, challenging the public health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.